In an opinion, the HAS takes up the bulk of the arguments that the European Medicines Agency (EMA) gave on Thursday. For this reason, he insists that it can be administered again without waiting any longer, since it has been shown with the people who have received it that it prevents hospitalizations due to covid by 94%.
However, as the EMA has identified a possible increased risk of thrombus for people under 55 years of age, France prefers to take time and not inject into that group while waiting for additional data to arrive.
In this regard, he recalls that in the next two months the vast majority of the priority group to receive vaccines will be those over that age. And those under 55 who are in priority groups may be given other vaccines.
The French Prime Minister, Jean Castex , 55, has wanted to personally contribute to eliminating the suspicions that AstraZeneca has generated and has been vaccinated this Friday with the Anglo-Swedish injectable.
It may interest you
France’s decision comes after the European Medicines Agency endorsed the safety of the Anglo-Swedish vaccine . Spain is another of the countries that has already announced that it will resume vaccination this next week , although the Ministry of Health has to rule on whether to modify the age groups that will receive this injectable.
In its resolution, the EMA considers that the vaccine developed by the Anglo-Swedish laboratory AstraZeneca “is a safe and effective option against covid19” and that “the benefits continue to outweigh the risk of side effects.” Although the investigation will continue with a more detailed analysis of the cases, including an evaluation of the other licensed vaccines, as well as the epidemiological studies, the EMA considers that they have reached a clear scientific conclusion.
That “the vaccine is not associated with an increase in the general risk of thrombi among those who receive it.” Of course, the research does not allow to exclude its relationship with very rare cases of blood clots associated with low levels of platelets in the blood, including rare cases of cerebral venous thrombosis (CVST). “A causal link with the vaccine has not been proven but it deserves a more detailed analysis,” the agency has said.